TABLE 3.
Clinical characteristics of kidney transplant patients according to their age and the time from kidney transplant to SARS-CoV-2 infection
| Age <65 years and time post-KT >6 months | Age <65 years and time post-KT ≤6 months | Age ≥65 years and time post-KT >6 months | Age ≥65 years and time post-KT ≤6 months | p value | |
|---|---|---|---|---|---|
| Patients, n | 575 | 53 | 350 | 33 | |
| Prednisone, n (%)a,b | 431 (78.4) | 50 (98) | 267 (78.5) | 29 (96.7) | .001 |
| Tacrolimus, n (%)a,b | 471 (85.6) | 51 (100) | 278 (81.8) | 29 (96.7) | .002 |
| Mycophenolate, n (%)a,b | 409 (74.4) | 47 (92.2) | 252 (74.1) | 25 (83.3) | .02 |
| mTOR inhibitors, n (%)a,b | 108 (19.6) | 2 (3.9) | 61 (17.9) | 3 (10) | .02 |
| Asymptomatic, n (%) | 68 (11.8) | 8 (15.1) | 21 (6) | 2 (6.1) | .01 |
| Gastrointestinal symptoms, n (%) | 202 (35.1) | 14 (26.4) | 101 (28.9) | 6 (18.2) | .04 |
| Pneumonia, n (%) | 348 (60.5) | 34 (64.2) | 262 (74.9) | 27 (81.8) | <.001 |
| Lymphopenia, n (%) | 359 (62.4) | 43 (81.1) | 258 (73.7) | 30 (90.9) | <.001 |
| Hospitalized, n (%) | 417 (72.5) | 45 (84.9) | 299 (85.4) | 30 (90.9) | <.001 |
| Ventilator support, n (%) | 67 (11.7) | 12 (22.6) | 67 (19.1) | 9 (27.3) | .001 |
| Non anti-COVID–19 therapy, n (%)c | 170 (29.6) | 11 (20.8) | 58 (16.6) | 3 (9.1) | <.001 |
| COVID–19 pharmacological treatment | |||||
| Hydroxychloroquine, n (%) | 250 (43.5) | 23 (43.4) | 184 (52.6) | 23 (69.7) | .003 |
| Glucocorticoids, n (%) | 259 (45) | 33 (62.3) | 188 (53.7) | 14 (42.4) | .01 |
| Tocilizumab, n (%) | 74 (12.9) | 14 (26.4) | 44 (12.6) | 9 (27.3) | .005 |
| Dead, n (%) | 65 (11.3) | 13 (24.5) | 124 (35.4) | 18 (54.5) | <.001 |
Note: All variables of the study were compared between the four groups, showing only those with p < .05.
Abbreviation: KT, kidney transplantation.
a
As baseline immunosuppressive treatment at the time of COVID-19 diagnosis.
b
Data of 971 patients: 550, 51, 340, and 30 patients from the 1st to the 4th group, respectively.
c
Non-anti-COVID-19 therapy includes the cases that have not received specific drugs against SARS-CoV-2 or against the inflammatory response due to COVID-19.